![The NAVigator artwork](https://is3-ssl.mzstatic.com/image/thumb/Podcasts113/v4/fc/89/c5/fc89c5fc-809c-cd04-9de3-860c238a530f/mza_6335031084024793720.jpg/100x100bb.jpg)
Tekla's Omstead: Great promise from 'a new generation' of health care firms
The NAVigator
English - July 16, 2021 13:00 - 10 minutes - 10.5 MB - ★★★★★ - 5 ratingsInvesting Business closedendfunds Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
Previous Episode: Bulldog's Goldstein on the hard path facing activist shareholders
Next Episode: Tax edge makes munis attractive even as discounts shrink
Dan Omstead, chief executive officer at Tekla Capital Management -- which sponsors four health-care oriented closed-end funds -- says that the pandemic proved the promise of health care and biotech companies as it helped vaccine maker Moderna grow from a small form to one of the largest health-care companies in the world, and now he is looking at 'a new generation of companies that are well funded and developing very innovative products against every health-care target you can imagine.'